Ipraxa Steri-Neb (Ipratropium Bromide Monohydrate)

Ipratropium Bromide is a bronchodilator used to manage airway obstruction in obstructive lung diseases.

• COPD: reduces bronchoconstriction and improves lung function.
• Asthma: provides additional bronchodilation for patients with persistent symptoms.
• Bronchospasm: relieves acute bronchospasm episodes by relaxing airway smooth muscle.
• Acute COPD exacerbations: helps restore airflow during worsening episodes.

• Ipratropium Bromide acts as a competitive antagonist at muscarinic M3 receptors on airway smooth‑muscle cells. By blocking acetylcholine binding, it prevents intracellular calcium increase, leading to relaxation of bronchial smooth muscle and reduced mucus secretion, thereby producing bronchodilation and improving airway patency in obstructive respiratory conditions. The effect is localized to the lungs because the drug is poorly absorbed systemically, minimizing systemic anticholinergic activity.

Ipratropium Bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: a persistent feeling of oral dryness that may increase thirst.
• Cough: a transient, non‑productive cough caused by airway irritation from the inhaled solution.
• Throat irritation: mild soreness or scratchy sensation in the throat after inhalation.
• Hoarseness: temporary alteration of voice quality, often resolving without intervention.

Serious or Rare Side Effects

• Paradoxical bronchospasm: an unexpected worsening of breathing difficulty shortly after use, requiring medical attention.
• Allergic reaction: skin rash, itching, swelling, or in severe cases, anaphylaxis that necessitates immediate care.
• Urinary retention: difficulty initiating or completing urination, more common in patients with prostate enlargement.
• Glaucoma exacerbation: increase in intra‑ocular pressure that may aggravate pre‑existing glaucoma.

When prescribing Ipratropium Bromide, clinicians should consider several safety and handling precautions.

• Assess respiratory status: confirm diagnosis of COPD or asthma before initiating therapy.
• Monitor for paradoxical bronchospasm: observe patients for worsening symptoms after first doses.
• Use with caution in patients with narrow-angle glaucoma: anticholinergic effects may increase intra‑ocular pressure.
• Evaluate urinary tract health: avoid in individuals with known urinary retention or prostate enlargement.
• Avoid concurrent use with other anticholinergic inhalers unless directed: may increase risk of systemic effects.
• Store at room temperature: keep the inhalation solution below 25°C, in the original container, protected from light and moisture.

Ipratropium Bromide can interact with other medications, altering efficacy or safety.

Major Interactions (Avoid)

• Concurrent use with other muscarinic antagonists (e.g., tiotropium): may increase anticholinergic burden and risk of side effects.
• Beta‑agonist overdose: combined bronchodilation may cause excessive cardiovascular stimulation.

Moderate Interactions (Monitor Closely)

• Anticholinergic systemic drugs (e.g., atropine, antihistamines): may enhance dry‑mouth and urinary retention.
• Inhaled corticosteroids: monitor for potential increased risk of oral thrush.
• Diuretics: watch for electrolyte disturbances if systemic absorption occurs.
• MAO inhibitors: observe for possible additive tachycardia.